These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30443223)

  • 1. The Role of Leukocytes in Diabetic Cardiomyopathy.
    Bajpai A; Tilley DG
    Front Physiol; 2018; 9():1547. PubMed ID: 30443223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocyte diversity in resolving and nonresolving mechanisms of cardiac remodeling.
    Tourki B; Halade G
    FASEB J; 2017 Oct; 31(10):4226-4239. PubMed ID: 28642328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
    Palomer X; Salvadó L; Barroso E; Vázquez-Carrera M
    Int J Cardiol; 2013 Oct; 168(4):3160-72. PubMed ID: 23932046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of FPR2 impaired leukocytes recruitment and elicited non-resolving inflammation in acute heart failure.
    Kain V; Jadapalli JK; Tourki B; Halade GV
    Pharmacol Res; 2019 Aug; 146():104295. PubMed ID: 31216426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy.
    Frati G; Schirone L; Chimenti I; Yee D; Biondi-Zoccai G; Volpe M; Sciarretta S
    Cardiovasc Res; 2017 Mar; 113(4):378-388. PubMed ID: 28395009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of microRNAs in the pathogenesis of diabetic cardiomyopathy.
    Liu X; Liu S
    Biomed Rep; 2017 Feb; 6(2):140-145. PubMed ID: 28357065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure?
    Nikolaidis LA; Levine TB
    Cardiol Rev; 2004; 12(3):158-70. PubMed ID: 15078585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splenic leukocytes define the resolution of inflammation in heart failure.
    Halade GV; Norris PC; Kain V; Serhan CN; Ingle KA
    Sci Signal; 2018 Mar; 11(520):. PubMed ID: 29511119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control.
    Borghetti G; von Lewinski D; Eaton DM; Sourij H; Houser SR; Wallner M
    Front Physiol; 2018; 9():1514. PubMed ID: 30425649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Inflammation in Heart Failure.
    Shirazi LF; Bissett J; Romeo F; Mehta JL
    Curr Atheroscler Rep; 2017 Jun; 19(6):27. PubMed ID: 28432635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-ischemic diabetic cardiomyopathy may initially exhibit a transient subclinical phase of hyperdynamic myocardial performance.
    Hensel KO
    Med Hypotheses; 2016 Sep; 94():7-10. PubMed ID: 27515189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression.
    Bulani Y; Sharma SS
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):255-267. PubMed ID: 28695302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies.
    Tarquini R; Pala L; Brancati S; Vannini G; De Cosmo S; Mazzoccoli G; Rotella CM
    Curr Med Chem; 2018; 25(13):1510-1524. PubMed ID: 28685679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic Cardiomyopathy: Impact of Biological Sex on Disease Development and Molecular Signatures.
    Toedebusch R; Belenchia A; Pulakat L
    Front Physiol; 2018; 9():453. PubMed ID: 29773993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart Failure in Type 2 Diabetes Mellitus.
    Kenny HC; Abel ED
    Circ Res; 2019 Jan; 124(1):121-141. PubMed ID: 30605420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy.
    Ritchie RH; Zerenturk EJ; Prakoso D; Calkin AC
    J Mol Endocrinol; 2017 May; 58(4):R225-R240. PubMed ID: 28373293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes and heart failure in the post-myocardial infarction patient.
    Estep JD; Aguilar D
    Curr Heart Fail Rep; 2006 Dec; 3(4):164-9. PubMed ID: 17129509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial metabolism in diabetic cardiomyopathy: potential therapeutic targets.
    Sung MM; Hamza SM; Dyck JR
    Antioxid Redox Signal; 2015 Jun; 22(17):1606-30. PubMed ID: 25808033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.
    Jia G; Hill MA; Sowers JR
    Circ Res; 2018 Feb; 122(4):624-638. PubMed ID: 29449364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia.
    Hokama JY; Ritter LS; Davis-Gorman G; Cimetta AD; Copeland JG; McDonagh PF
    J Diabetes Complications; 2000; 14(2):96-107. PubMed ID: 10959072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.